Immunotropic effects of hypoglycemic agents on coronavirus infection: a view from the perspective of pharmacogenetics

Diabetes mellitus is a predictor of the severe course new coronavirus infection and high mortality, in this regard, selection appropriate hypoglycemic therapy vital issue. In article, we paid attention to dipeptidyl peptidase-4 (DPP-4) inhibitors, since group drugs has features like low risk hyperglycemia immuno-mediated effects. For most effective treatment, it necessary take into account individual characteristics each patient, namely, achievements pharmacogenetics. The genetic variability response with DPP-4 inhibitors due variety polymorphisms, several main variations are considered review. ambiguity available studies on effectiveness patients type 2 diabetes COVID-19 indicates need continue pharmacogenetic studies. combination knowledge about subtleties mechanisms pharmacological action pharmacodinamics will ensure greatest safety personalized against background infection.